S 19752

Drug Profile

S 19752

Latest Information Update: 03 Nov 2003

Price : $50

At a glance

  • Originator Servier
  • Class Anti-inflammatories; Dipeptides
  • Mechanism of Action Neurokinin 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Chronic obstructive pulmonary disease

Most Recent Events

  • 03 Nov 2003 No development reported - Preclinical for Chronic obstructive pulmonary disease in France (unspecified route)
  • 09 Jul 1997 New profile
  • 09 Jul 1997 Preclinical development for Chronic obstructive pulmonary disease in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top